This is a working overview of peptide drug, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-19. Anything still debated is marked as such rather than presented as settled.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Reversed-phase HPLC (RP-HPLC) is the most widespread mode of chromatography. It has a non-polar stationary phase and an aqueous, moderately polar mobile phase. RP-HPLC is so commonly used among the biologists and life science users, that it is often referred to as simply "HPLC". The pharmaceutical industry also regularly employs RP-HPLC to qualify drugs before their release. In the reversed phase methods, the substances are retained in the system the more hydrophobic they are. For the retention of organic materials, the stationary phases, are consisted mainly of porous granules of silica gel packed in the column. In shape, they are usually spheres of varying diameters (sub-2, 3, 5, 7, 10 μm), varying pore diameters (60, 100, 150, 300 Å). On their surface are chemically bonded straight chain alkyl ligands, such as C3, C4, C8, C18. The number counts the carbon atoms in a ligand. For example, a C3 ligand is a propyl. The longer the hydrocarbon ligand on the stationary phase, the longer the sample components can be retained. Most of the current methods of separation of biomedical materials use C18 stationary phase, sometimes called by a trade names such as ODS (octadecylsilane) or RP-18 (Reversed Phase 18). To make such stationary phases, one treat the surface of silica gel particles with RMe2SiCl, where R is a straight chain alkyl group such as C18H37 or C8H17. To separate aromatic compounds, or in general compounds with many pi bonds, the stationary phase can have phenyl surface ligands. At pH < 2, the bond between the ligand and the silica gel may dissolve.
==== Binding to L7/L12 ==== L7/L12 is only a multicopy protein on the large ribosomal subunit of the bacterial ribosome that binds to certain GTPases, like Initiation Factor 2, Elongation factor-Tu, Release Factor 3, and EF-G. Specifically, the C-terminal of L7/L12 will bind to EF-G and is necessary for GTP hydrolysis.
=== Books === Two biographies have been written about Staley, both authored by Adriana Rubio—Layne Staley: Angry Chair released in 2003, which contains an alleged final interview of Staley that Rubio claimed to have conducted less than three months before his death, and Layne Staley: Get Born Again, released in 2009, a revised and updated version of her earlier book. Staley's family has disputed Rubio's work, stating they do not believe she interviewed him in 2002. When questioned about the authenticity of the book, Rubio refused to confirm the interview was genuine. Staley's last interview was for the radio program Rockline on July 19, 1999, promoting the release of the compilation album Nothing Safe: Best of the Box with the other members of Alice in Chains. The content of Rubio's book, including what she referred to as Staley's final interview, was called into question in journalist David De Sola's 2015 book Alice in Chains: The Untold Story. De Sola questions not only the content of the interview, which portrays Staley as using his lyrics in casual conversation, it also indicates that Rubio never spoke to him, citing her refusal to release the tape with the interview and the fact that not even her publisher had access to the tape. One of Staley's sisters, Liz Coats, likewise doubted the veracity of the book. Staley was featured on the books Grunge Is Dead: The Oral History of Seattle Rock Music (2009) by Greg Prato, and Everybody Loves Our Town: An Oral History of Grunge (2011) by Mark Yarm.
The system is usually baked, preferably under vacuum, to temporarily raise the vapour pressure of all outgassing materials in the system and boil them off. If necessary, this outgassing of the system can also be performed at room temperature, but this takes much more time. Once the bulk of the outgassing materials are boiled off and evacuated, the system may be cooled to lower vapour pressures to minimize residual outgassing during actual operation. Some systems are cooled well below room temperature by liquid nitrogen to shut down residual outgassing and simultaneously cryopump the system. In ultra-high vacuum systems, some very odd leakage paths and outgassing sources must be considered. The water absorption of aluminium and palladium becomes an unacceptable source of outgassing, and even the absorptivity of hard metals such as stainless steel or titanium must be considered. Some oils and greases will boil off in extreme vacuums. The porosity of the metallic vacuum chamber walls may have to be considered, and the grain direction of the metallic flanges should be parallel to the flange face. The impact of molecular size must be considered. Smaller molecules can leak in more easily and are more easily absorbed by certain materials, and molecular pumps are less effective at pumping gases with lower molecular weights. A system may be able to evacuate nitrogen (the main component of air) to the desired vacuum, but the chamber could still be full of residual atmospheric hydrogen and helium.
== Return to competition == In 1988, the IOC formed the Apartheid and Olympism Commission, including Kevan Gosper, the SCSA, and SANROC. While SANOC agreed it could not seek readmission to the IOC until apartheid was dismantled, negotiations to prepare the way for South Africa's reintegration into world sport proceeded in tandem with the political negotiations to end apartheid. Within South Africa, in each sport there were competing race-specific and multi-racial bodies, which would have to merge into one in order to affiliate into both a nonracial NOC and the IF for its sport. ANOCA took the lead in negotiations in 1990 and 1991, and an Interim National Olympic Committee of South Africa (INOCSA) was formed with Sam Ramsamy as president. Ramsamy had been a leading anti-apartheid campaigner and advocate of sports boycotts. In June 1991, the Population Registration Act, 1950, a cornerstone of apartheid legislation, was repealed by the government of F. W. de Klerk, and in July an INOCSA delegation met with the Apartheid and Olympism Commission at the IOC headquarters in Lausanne. The IOC recognised INOCSA on 9 July 1991, such that the "interim" was removed from its name (NOCSA). It first competed at the 1992 Summer Olympics in Barcelona. The official flag of South Africa and national anthem "Die Stem van Suid-Afrika" were still the apartheid-era ones, but the Olympic team competed under an interim flag and Ludwig van Beethoven's "Ode to Joy". Likewise it decided not to use the Springbok emblem or green-and-gold colours of white sports teams.
Sources: en.wikipedia.org
=== 2010s === 2010: Marcia McNutt became the first female director of the United States Geological Survey. 2016: Marcia McNutt became the first woman president of the American National Academy of Sciences. 2018: Frances Arnold received the Nobel Prize in Chemistry "for the directed evolution of enzymes"; she shared it with George Smith and Gregory Winter, who received it "for the phage display of peptides and antibodies". This made Frances the first American woman to receive the Nobel Prize in Chemistry. 2019: Karen Uhlenbeck won the Abel Prize for "her pioneering achievements in geometric partial differential equations, gauge theory, and integrable systems, and for the fundamental impact of her work on analysis, geometry and mathematical physics." She is the first woman to win the prize.
== Early years == Ned Lagin was born in New York City and raised on Long Island in Roslyn Heights, New York. Growing up, Lagin was influenced by classical and jazz music, and the modern music and art cultures of New York City in the 1960s. He started photography with a Kodak Baby Brownie Special at the age of five, and piano lessons and science, natural history, and electronic projects at the age of six. He attended the Wheatley School in Old Westbury, New York, was awarded two National Science Foundation Scholarships, and attended the Massachusetts Institute of Technology with the intention of becoming an astronaut. Lagin received a degree in molecular biology and humanities from MIT in 1971, where he studied with John Harbison, Gregory Tucker, David Epstein, Noam Chomsky, Gian-Carlo Rota, Salvador Luria, and Jerome Lettvin. Chomsky's generative grammar concepts inspired Lagin's thinking about creating generative music forms (1968), and Lettvin connected him to the writings of Norbert Wiener and Warren McCulloch, and more generally to cybernetics. While at MIT, Lagin also completed jazz coursework at the Berklee School of Music. He was deeply influenced by the jazz world in New York City, particularly pianist Bill Evans, whom he met in Boston and saw perform many times in New York and Boston in the late 1960s and early 1970s. After becoming acquainted with each other, Evans wrote out some of his tunes for Lagin. During this period, his piano teachers included Dean Earl (a former Charlie Parker sideman) and Ray Santisi (a sideman with Parker, Stan Getz and Dexter Gordon).
The name and coat of arms of the present state go back to the Germanic tribe of Saxons. During the Migration Period some of the Saxon peoples left their homeland in Holstein about the 3rd century and pushed southwards over the Elbe, where they expanded into the sparsely populated regions in the rest of the lowlands, in present-day Northwest Germany and the northeastern part of what is now the Netherlands. From about the 7th century the Saxons had occupied a settlement area that roughly corresponds to the present state of Lower Saxony, of Westphalia and a number of areas to the east, for example, in what is now west and north Saxony-Anhalt. The land of the Saxons was divided into about 60 Gaue. The Frisians had not moved into this region; for centuries they preserved their independence in the most northwesterly region of the present-day Lower Saxon territory. The original language of the folk in the area of Old Saxony was West Low German, one of the varieties of language in the Low German dialect group.
== Side effects == Side effects of orexin receptor antagonists include somnolence, daytime sleepiness and sedation, headache, abnormal dreams, fatigue, and dry mouth. Rates of somnolence or fatigue with orexin receptor antagonists in clinical trials were 7% (vs. 3% with placebo) for suvorexant 15 to 20 mg, 7 to 10% (vs. 1.3% for placebo) for lemborexant 5 to 10 mg, and 5 to 6% (vs. 4% with placebo) for daridorexant 25 to 50 mg.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.